Abstract
Dear Editor, We read with great interest the provocative findings of Ghalawinji et al ( 1). In brief, 72% of patients discontinue long-term cortisol-lowering therapy. This surprisingly high rate raises important questions about the management of such patients and may reposition the role of bilateral adrenalectomy after failed transsphenoidal surgery ( 2). However, we believe that this rate should be considered with caution as it is derived from a real-life study in an expert center with dedicated postoperative procedures and might not replicate the true rate of discontinuation of drug treatment. The study also raises other interesting points, which will be discussed in the following paragraphs. First, it is important to note that the authors always gave priority to curative treatment, either with a second operation or with radiotherapy, whenever possible, and regardless of the cortisol level achieved with drug treatment. Thus, 4 patients underwent surgery while the drug was effective and well tolerated. In addition, 6 women of childbearing age were offered bilateral adrenalectomy because they wanted to become pregnant, and no drug (except cabergoline) was approved for use during pregnancy. The authors mentioned that these women were uncontrolled but did not provide the dose of drug treatment at that time. This raises the possibility of suboptimal use of drug treatment, as already shown in our multicenter study on ketoconazole: the median dose of ketoconazole was only 800 mg/day in uncontrolled patients (49%), despite the fact that tolerance was good ( 3). We therefore believe that the 72% discontinuation rate is overestimated and could easily be revised to less than 50%. The results could thus be closer to those reported in prospective studies where, with the exception of pasireotide, only 30% of patients discontinued treatment at the end of the studies, for instance with osilodrostat ( 4).

This publication has 6 references indexed in Scilit: